Waksal's Kadmon acquires Three Rivers

The Kadmon Pharmaceuticals LLC unit of Kadmon Corp. LLC (New York, N.Y.) acquired Three Rivers Pharmaceuticals LLC (Warrendale, Pa.) for $100 million in cash and equity. Three Rivers markets products for infectious diseases and cancer, including HCV drug Infergen interferon alfacon-1 and fungal infection treatment Amphotec amphotericin B. Three Rivers also is developing a portfolio of generic cancer products. Kadmon said the acquisition provides a commercial platform from which it can expand its pipeline in cancer, infectious diseases and immunology. Kadmon said the acquisition was financed through debt and equity capital. Colbeck Capital Management advised Kadmon. ...